Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Antibodies

Apolipoprotein A-I Antibody

Product Sizes
1 mg
£1409.00
600-101-196-1MG
About this Product
SKU:
600-101-196
Additional Names:
Apoa1|goat anti-Apolipoprotein A-I Antibody, goat anti-APOA1 antibody, goat anti-APO-A1 antibody, goat anti-APOA-1 antibody, APOA1/APOC3 fusion gene antibody, Apolipoprotein A I precursor antibody, Apolipoprotein AI antibody, Apolipoprotein of high density lipoprotein antibody, ProapoA-I, Proapolipoprotein A-I
Application:
ELISA, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot
Buffer:
0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA
CE/IVD:
RUO
Clonality:
Polyclonal
Concentration:
1 mg/ml
Extra Details:
Anti Apolipoprotein A-I antibody recognizes the gene product of APOA1. Apolipoprotein promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A-I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18-amino acid signal peptide is removed co-translationally and a 6-amino acid propeptide is cleaved post-translationally. Variation in the latter step, in addition to modifications leading to so-called isoforms, is responsible for some of the polymorphism observed. APOA1 is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the C-III gene is transcribed convergently in relation to A-I. Defects in the apolipoprotein A-1 gene are associated with HDL deficiency and Tangier disease. This antibody is suitable for cardiovascular research.
Formulation:
0.125 M Sodium Borate, 0.075 M Sodium Chloride, 0.005 M EDTA, pH 8.0
Host:
Goat
Immunogen:
apoLipoprotein Type A-I was isolated from mouse plasma by density gradient centrifugation followed by HPLC purification.
Isotype:
IgG
Physical State:
Liquid
Reactivities:
Mouse
Shipping Conditions:
Blue Ice
Specificity:
This product has been prepared by immunoaffinity chromatography using immobilized antigens followed by extensive cross-adsorption against other apoLipoproteins and human serum proteins to remove any unwanted specificities. Typically less than 1% cross-reactivity against other types of apoLipoprotein was detected by ELISA against purified standards. This antibody reacts with mouse apoLipoprotein A-
Storage Conditions:
-20[o]C 50% glycerol. Aliquot. Avoid freeze/thaw cycles., 2-8[o]C diluted. Aliquot. Avoid freeze/thaw cycles.
Supplier:
Rockland Inc
Type:
Antibody: Polyclonal Antibody
Immunofluorescence of Anti-Apolipoprotein AI. Versican colocalizes with HDL isolated from AgNO3-injected mice at the cell surface of 3T3-L1 adipocytes. Free SAA and HDL from PBS- or AgNO3-injected C57BL/6 mice were isolated. Some adipocytes were transfected with siRNA specific for versican (Vcan) for 3 days. After exposure to free SAA (15 ug/mL) and/or these HDL preparations (50 ug protein/mL) for 6 hours, 3T3-L1 adipocytes were fixed in 2% formalin for 5 minutes. After extensively washing, (A) APOA1 and versican were stained using anti-versican (shown in red) and anti-APOA1 (shown in green) antibodies, or (B) SAA and versican were stained using anti-versican (shown in red) and anti-SAA (shown in green) antibodies and photographed by fluorescence microscopy (Nikon Eclipse 80i, original magnification, x200). Cell nuclei were counterstained with DAPI (blue). Cell morphology was shown by phase-contrast photography (left). Merged fluorescence (overlay) is shown in yellow. Figure 2. PMID: 32970631.
Immunohistochemistry of Anti-Apolipoprotein AI. Immunohistochemical staining of versican and biglycan shows a similar distribution with the staining of SAA and APOA1 in the epididymal white adipose tissue from mice fed an HFHS diet and in the omental fat tissue from human obese subjects undergoing gastric bypass surgery. (A) Mice were fed a chow or HFHS diet for 16 weeks, after which adipose tissue was obtained and immunostained with the antibodies shown. Tissues were photographed using microscopy (original magnification, x60). Quantitation of the immunostaining is shown in the lower panel (n = 5-7, mean +/- SEM). *P < 0.001 vs. chow. (B) Omental fat was obtained from gastric bypass patients and immunostained with the antibodies shown. Tissues were photographed using microscopy (original magnification, x60). The pictures of MAC2, CD68, versican, and biglycan staining are from our previous publication (17); APOA1 and SAA staining were performed on adjacent sections. Figure 1. PMID: 32970631.
Western Blot of Anti-Apolipoprotein AI. Proteomics confirmation and hepatic gene expression. A: HDL preparations from the indicated treatment groups were subjected to immunoblot and probed for Saa (marker = 15 kD) and Apoa1 (marker = 35 kD). Densitometry was performed using ImageJ software. Control HDL samples were pooled; n = 3 for treatment groups. Different letters indicate significant differences, assessed using one-way ANOVA with multiple comparisons (Tukey) (P < 0.05). cH, control HDL from mice injected with saline; CR-HDL, HDL from mice fed an HFHS diet that were calorically restricted; 10,12-HDL, HDL from mice fed an HFHS diet containing 10,12 CLA; HFHS-HDL, HDL from mice fed an HFHS diet; sH, HDL from mice injected with silver nitrate. B: Liver gene expression was quantified from the indicated treatment groups. n = 8 mice/group, *P < 0.05 from HFHS. Fig. 5. PMID: 35714730.
Immunofluorescence of Anti-Apolipoprotein AI. HDL isolated from AgNO3-injected mice colocalizes with biglycan at the cell surface of peritoneal macrophages. HDL from PBS- and AgNO3-injected C57BL/6 mice was isolated. After exposure to these HDL preparations (50 ug protein/mL) for 6 hours, TG-elicited peritoneal macrophages from Saa3-/- were fixed in 2% formalin for 5 minutes (A and B). After extensive washing, (A) APOA1 and biglycan were stained using anti-biglycan (red) and anti-APOA1 (green) antibodies, or (B) SAA and biglycan were stained using anti-biglycan (red) and ant-SAA (green) antibodies and photographed by fluorescence microscopy (Nikon Eclipse 80i, original magnification, x200). Figure 5. PMID: 32970631.
Western Blot of Anti-Apolipoprotein AI. Lipoprotein particle remodeling is induced by the interaction of nascent LpA-I (apo AI [apolipoprotein AI] containing particles formed by incubating ABCA1 [ATP-binding cassette transporter 1]-expressing cells with apo AI) and HDL3 in vitro. Fluorescently labeled LpA-I (Cy5.5-LpA-I) and HDL3 (DL488-HDL3) were incubated for 1 h at 37°C, final concentration of each lipoprotein was 0.5 mg/mL. Lipoproteins were subjected to nondenaturing polyacrylamide gradient gel electrophoresis. Cy5.5-apo AI (left) and DL488-apo AI (middle) were visualized by fluorescent imaging, apo AI (right) was detected by anti-apo AI antibody. The migration of lipid-poor apo AI is also indicated. HDL indicates high-density lipoprotein. Figure 3. PMID: 32131613.